Julie Gerberding latest transaction was an Uninformative Buy of $702.02K.
What was Julie Gerberding's most profitable transaction?
Julie Gerberding’s most profitable transaction was an Informative Sell of MRK stock on November 8, 2016. The return on the trade was 3.70%.
What is Julie Gerberding's role in Merck & Company?
Julie Gerberding's role in Merck & Company is EVP, Chief Patient Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.